Loading…
Loading…
Loading…
Loading…
Loading…
Loading…
Loading…
Loading…
Loading…
Loading…
Loading…
Loading…
JNJ-95475939 (JNJ-5939) is an investigational Johnson & Johnson candidate evaluated in the Phase 2b DUPLEX-AD study in atopic dermatitis.
Also known as: JNJ-5939, JNJ-95475939
JNJ-95475939 (JNJ-5939) is an investigational Johnson & Johnson candidate evaluated in the Phase 2b DUPLEX-AD study in atopic dermatitis. It is a investigational therapy developed by Johnson & Johnson.
JNJ-95475939's mechanism is summarized above; see the linked trial readouts for details.
Open any benchmark below to see the full model leaderboard scored by accuracy, Brier score, and log loss. Models forecast each readout before it is public, so the scores reflect genuine predictive skill rather than hindsight.